Cargando…
Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada
BACKGROUND: Treatment guidelines suggest either a low-dose or high-dose approach when prescribing amikacin for nontuberculous mycobacterial pulmonary disease (NTM PD), but data supporting the low-dose approach are limited. The purpose of this study was to describe the safety and efficacy of the use...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547538/ https://www.ncbi.nlm.nih.gov/pubmed/31159865 http://dx.doi.org/10.1186/s40360-019-0302-1 |
_version_ | 1783423700386709504 |
---|---|
author | Aznar, Maria Luisa Marras, Theodore K. Elshal, Ahmed Said Mehrabi, Mahtab Brode, Sarah K. |
author_facet | Aznar, Maria Luisa Marras, Theodore K. Elshal, Ahmed Said Mehrabi, Mahtab Brode, Sarah K. |
author_sort | Aznar, Maria Luisa |
collection | PubMed |
description | BACKGROUND: Treatment guidelines suggest either a low-dose or high-dose approach when prescribing amikacin for nontuberculous mycobacterial pulmonary disease (NTM PD), but data supporting the low-dose approach are limited. The purpose of this study was to describe the safety and efficacy of the use of a low-dose of intravenous amikacin in a cohort of patients with NTM PD. METHODS: We retrospectively reviewed all patients with NTM PD who received amikacin at our institution between July 1, 2003 and February 28, 2017. Demographics, clinical, microbiological and radiological data, indication and dose of amikacin, and adverse drug effects were recorded. RESULTS: A total of 107 patients received a regimen containing amikacin for a median (IQR) of 7 (4–11) months. Seventy (65.4%) were female and the mean age (SD) was 58.3 (14.9) years. Amikacin was started at a median dose of 9.9 (2.5) mg/kg/day. Ototoxicity was observed in 30/77 (39%) patients and it was related to female sex (OR 4.96, 95%CI 1.24–19.87), and total dose of amikacin per bodyweight (OR 1.62, 95%CI 1.08–2.43). Patients of East Asian ethnicity were less likely to develop ototoxicity (0.24, 95%CI 0.06–0.95). Out of 96 patients who received amikacin for more than 3 months, 65 (67.7%) experienced symptom improvement and 30/62 (49.2%) converted their sputum to culture negative within a year. CONCLUSIONS: Patients with NTM PD treated with low-dose intravenous amikacin frequently developed ototoxicity, which was associated with female sex, and total dose of amikacin per bodyweight. Physicians should carefully consider dose, treatment duration, and long term prognosis in balancing risks and benefits of intravenous amikacin in NTM PD. |
format | Online Article Text |
id | pubmed-6547538 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-65475382019-06-06 Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada Aznar, Maria Luisa Marras, Theodore K. Elshal, Ahmed Said Mehrabi, Mahtab Brode, Sarah K. BMC Pharmacol Toxicol Research Article BACKGROUND: Treatment guidelines suggest either a low-dose or high-dose approach when prescribing amikacin for nontuberculous mycobacterial pulmonary disease (NTM PD), but data supporting the low-dose approach are limited. The purpose of this study was to describe the safety and efficacy of the use of a low-dose of intravenous amikacin in a cohort of patients with NTM PD. METHODS: We retrospectively reviewed all patients with NTM PD who received amikacin at our institution between July 1, 2003 and February 28, 2017. Demographics, clinical, microbiological and radiological data, indication and dose of amikacin, and adverse drug effects were recorded. RESULTS: A total of 107 patients received a regimen containing amikacin for a median (IQR) of 7 (4–11) months. Seventy (65.4%) were female and the mean age (SD) was 58.3 (14.9) years. Amikacin was started at a median dose of 9.9 (2.5) mg/kg/day. Ototoxicity was observed in 30/77 (39%) patients and it was related to female sex (OR 4.96, 95%CI 1.24–19.87), and total dose of amikacin per bodyweight (OR 1.62, 95%CI 1.08–2.43). Patients of East Asian ethnicity were less likely to develop ototoxicity (0.24, 95%CI 0.06–0.95). Out of 96 patients who received amikacin for more than 3 months, 65 (67.7%) experienced symptom improvement and 30/62 (49.2%) converted their sputum to culture negative within a year. CONCLUSIONS: Patients with NTM PD treated with low-dose intravenous amikacin frequently developed ototoxicity, which was associated with female sex, and total dose of amikacin per bodyweight. Physicians should carefully consider dose, treatment duration, and long term prognosis in balancing risks and benefits of intravenous amikacin in NTM PD. BioMed Central 2019-06-03 /pmc/articles/PMC6547538/ /pubmed/31159865 http://dx.doi.org/10.1186/s40360-019-0302-1 Text en © The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Aznar, Maria Luisa Marras, Theodore K. Elshal, Ahmed Said Mehrabi, Mahtab Brode, Sarah K. Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada |
title | Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada |
title_full | Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada |
title_fullStr | Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada |
title_full_unstemmed | Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada |
title_short | Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada |
title_sort | safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in toronto, canada |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547538/ https://www.ncbi.nlm.nih.gov/pubmed/31159865 http://dx.doi.org/10.1186/s40360-019-0302-1 |
work_keys_str_mv | AT aznarmarialuisa safetyandeffectivenessoflowdoseamikacininnontuberculousmycobacterialpulmonarydiseasetreatedintorontocanada AT marrastheodorek safetyandeffectivenessoflowdoseamikacininnontuberculousmycobacterialpulmonarydiseasetreatedintorontocanada AT elshalahmedsaid safetyandeffectivenessoflowdoseamikacininnontuberculousmycobacterialpulmonarydiseasetreatedintorontocanada AT mehrabimahtab safetyandeffectivenessoflowdoseamikacininnontuberculousmycobacterialpulmonarydiseasetreatedintorontocanada AT brodesarahk safetyandeffectivenessoflowdoseamikacininnontuberculousmycobacterialpulmonarydiseasetreatedintorontocanada |